[Ki-67 and cyclin A--prognostic factors in breast cancer. Time to introduce proliferation markers in clinical routine].
Ahlin
Cecilia
C
Gynonkologiska kliniken, Universitetssjukhuset, Orebro. ahlins.post@telia.com
Fernö
Mårten
M
Amini
Rose-Marie
RM
Tolockiene
Egle
E
Blomqvist
Carl
C
Bergh
Jonas
J
Fjällskog
Marie-Louise
ML
D000970:Antineoplastic Agents / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000378:metabolism*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000473:pathology*; D049109:Cell Proliferation; D017024:Chemotherapy, Adjuvant; D019925:Cyclin A / Q000378:metabolism*; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D019394:Ki-67 Antigen / Q000378:metabolism*; D008940:Mitotic Index; D011379:Prognosis; D015203:Reproducibility of Results
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D019925:Cyclin A; D019394:Ki-67 Antigen